Effect of subanesthetic dose of esketamine on postoperative rehabilitation in frailty patients undergoing hip arthroplasty

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600126626

Enrollment

Unknown

Registered

2026-06-12

Start date

2024-04-04

Completion date

Unknown

Last updated

2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femoral neck fracture

Interventions

A group:esketamine

B group:sufentanil

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. American Society of Anesthesiologists (ASA) classification II or III. 2. Patients scheduled for hip replacement surgery due to a femoral neck fracture. 3. Over 65 years old. 4. No mental illness and able to cooperate with the survey. 5. Assessed using the FRAIL frailty scale, with a score of 3 or higher.

Exclusion criteria

Exclusion criteria: 1. There are communication barriers. 2. Experimental drug contraindications or allergies. 3. History of drug abuse. 4. Abnormal blood clotting.

Design outcomes

Primary

Measure	Time frame
24h Quality of Recovery;	—

Secondary

Measure	Time frame
VAS score on activity;IL-6;HAD score and Harris score;VAS score at rest;	—

Countries

China

Contacts

Public ContactXin Wenqi

Huai He Hospital of Henan University

xwq_mzk@163.com+86 371 2390 6562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026